UBS raised the firm’s price target on Illumina (ILMN) to $135 from $120 and keeps a Neutral rating on the shares. Encouraging clinical signals were the story of the quarter and guidance, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ILMN:
- Illumina price target lowered to $150 from $155 at Evercore ISI
- Illumina price target lowered to $120 from $130 at JPMorgan
- Closing Bell Movers: Amazon slammed 10% on earnings, dragging down futures
- Illumina reports Q4 adjusted EPS $1.35, consensus $1.23
- Illumina sees FY26 adjusted EPS $5.05-$5.20, consensus $5.07